Sleeping Aids Market Share, Size, Trends, Industry Analysis Report, By Product (Mattresses & Pillows, Sleep Laboratories, Medications, and Sleep Apnea Devices); By Sleep Disorders; By Region; Segment Forecast, 2023 - 2032
- Published Date:Jun-2023
- Pages: 114
- Format: PDF
- Report ID: PM2287
- Base Year: 2022
- Historical Data: 2019-2021
Report Outlook
The global sleeping aids market was valued at USD 67.51 billion in 2022 and is expected to grow at a CAGR of 6.8% during the forecast period.Sleep is one of the primary biological needs that aid in maintaining metabolic homeostasis cognitive functions and influences memory. These aids are medical devices and drugs that are used to diagnose & treat different types of sleep disorders, including insomnia, sleep apnea, narcolepsy, and others.
To Understand More About this Research: Request a Free Sample Report
These sleeping disorders negatively impact human health and lead to chronic diseases, including high blood pressure, arthritis, stroke, and diabetes. The growing focus of the global population on the adverse effects of this disorder is anticipated to drive the growth of the sleeping aids industry. However, the rising complexity concerns in sleep disorder treatment due to the introduction of new technologies are expected to hinder the development of the sleeping aids market. Further, the lack of proper documentation for the licensing and usage of pills and the improper standardization of sleeping aids devices are estimated to impact the sleeping aids industry negatively.
The COVID-19 outbreak has led to declining demand for sleeping aids due to widespread financial stress. Further, the spread of COVID-19 reflects the downfall in the sleeping aids industry growth because of the significant disruptions in the supply chain and the slowdown in production activities. The disruptions in the supply chain, lockdown measures, and limited consumer spending are anticipated to hamper sleeping aids industry development.
On the other side, it is projected that the market for sleep aids will expand due to the rising drug intake by SDB (Sleep-Disordered Breathing) patients at a high risk of experiencing various negative results from viral infection. The demand for sleep aids is anticipated to increase as governments worldwide relax their stance on lockdowns. In the post-pandemic period, market growth is predicted to be boosted by continuous product improvements and changing laws in various applications.
Industry Dynamics
Growth Drivers
The primary factor driving the growth of the sleeping aids market is the changing sleep pattern of the global population triggered by changing lifestyles. Further, the increasing affluence of consumers and improved access to medical services due to the rising demand for quality healthcare is anticipated to drive market growth. Moreover, the growing approval of new products in the market and the increasing government funding for research & development are expected to offer huge sleep aids industry growth opportunities.
The increasing M&A (Merger & Acquisition) among industry players to expand their product portfolio and geographic presence is anticipated to drive market growth. For instance, in September 2018, Tris Pharma acquired NextWave, a subsidiary of Pfizer. This acquisition will expand Tris Pharma’s product portfolio for treating ADHD patients. Furthermore, the rising innovation in sleeping aids devices and the developing of proper drugs for inappropriate sleep with fewer side effects are anticipated to boost global demand.
Report Segmentation
The market is primarily segmented based on product, sleep disorders, and region.
|
By Product |
By Sleep Disorders |
By Region |
|
|
|
To Understand the Scope of this Report: Speak to Analyst
The insomnia segment accounted for the largest share in 2022
The insomnia segment is recorded to hold the largest share in 2022 and is expected to lead the sleeping aids industry in the forecasting years. Insomnia is a disorder that causes difficulty in falling or staying asleep. Common causes of this disorder include chronic stress, depression, pain, and others. The huge share of the segment can be attributed to the increasing prevalence of the disease globally.
According to American Sleep Association, over 70 billion of the population in the U.S. suffers from this disorder. Out of which, over 33-50% of the population shows symptoms of Insomnia, while 10% have chronic insomnia. Moreover, the growing treatment trials are anticipated to grow the segment. For instance, in May 2019, Merck’s BELSOMRA C-IV met the primary endpoint in the phase 3 trial for Insomnia treatment in patients with mild to moderate dementia and Alzheimer's.
The Sleep Apnea segment is projected to show the fastest growth rate in the forecasting years. The rising sleep apnea testing is driving the growth of the segment. Further, the growing adoption of CPAP (Continuous Positive Airway Pressure) devices is anticipated to boost the segment’s growth. CPAP devices are devices used as a treatment for Sleep Apnea. This device aid in maintaining proper sleep and offer relief from snoring.
The development of innovative CPAP devices by manufacturers is anticipated to drive the segment’s growth. Moreover, the increasing number of patients affected with OSA (Obstructive Sleep Apnea) is expected to provide growth opportunities for the segment. The rising product developments for Sleep Apnea are anticipated to drive the segment’s growth. For instance, in October 2019, Fisher & Paykel released new OSA masks in the US.
North America accounted for the highest market shares in the global market in 2022.
North America accounted for the highest market shares in the global market in 2022. This huge market share can be attributed to the high prevalence of sleeping disorders due to increased alcohol and cigarette consumption in North America. Furthermore, the presence of key industry players in the U.S., along with the rising consumer awareness related to sleep quality and sleeping aids products, is anticipated to boost the market’s growth. The rise in the obese and geriatric population in the U.S. is expected to drive the demand for sleeping aids, medication, and devices.
Moreover, the Asia Pacific sleeping aids market is anticipated to exhibit the highest CAGR over the forecasting years. The fast growth of the industry in the Asia Pacific can be attributed to the increasing per capita income coupled with the growing knowledge regarding the negative effects of sleeping disorders among the population. Further, the changing lifestyle, having scaled stressful working hours along with the increasing number of younger people, is anticipated to offer huge market growth opportunities. Additionally, the rising trend toward using OTC (Over The Counter) medication is expected to drive the market’s growth in emerging nations such as India, China, and Japan.
Competitive Insight
Some of the major players operating in the global market include AstraZeneca Plc, Biodiem, Cadwell Industries Inc., Compumedics Limited, CSL Limited, Drive, Devilbiss Healthcare, Emergent Biosolutions, F.Hoffmann-La Roche Ltd., Gamma Vaccines Pty Ltd., GlaxoSmithKline Plc, Koninklijke Philips N.V., Merck & Co., Inc., Natus Medical Incorporated, Novartis AG, Pfizer Inc., Sanofi, Sinovac Biotech Ltd., and Sleepmed Inc.
Recent Developments
- in June 2022, Sleep Habit introduced Sleep Reset, a digital and personalized sleep clinic product. It leverages clinically tested techniques through its iOS and Android applications to identify and tackle the underlying factors contributing to individuals' sleep problems.
- In May 2022, StimScience unveiled Somnee, a consumer support offering. Somnee is an innovative headband that utilizes personalized, non-intrusive brain stimulation to enhance the sleep quality of its users. It marks the first-ever electronic sleep aid of its kind.
Sleeping Aids Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2023 |
USD 72.10 billion |
|
Revenue forecast in 2032 |
USD 130.34 billion |
|
CAGR |
6.8% from 2023 – 2032 |
|
Base year |
2022 |
|
Historical data |
2019 – 2021 |
|
Forecast period |
2023 – 2032 |
|
Quantitative units |
Revenue in USD billion/billion and CAGR from 2023 to 2032 |
|
Segments Covered |
By Product, By Sleep Disorders, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Key Companies |
AstraZeneca Plc, Biodiem, Cadwell Industries Inc., Compumedics Limited, CSL Limited, Drive, Devilbiss Healthcare, Emergent Biosolutions, F.Hoffmann-La Roche Ltd., Gamma Vaccines Pty Ltd., GlaxoSmithKline Plc, Koninklijke Philips N.V., Merck & Co., Inc., Natus Medical Incorporated, Novartis AG, Pfizer Inc., Sanofi, Sinovac Biotech Ltd., and Sleepmed Inc. |
FAQ's
The global sleeping aids market size is expected to reach USD 130.34 Billion by 2032.
Top market players in the Sleeping Aids Market are AstraZeneca Plc, Biodiem, Cadwell Industries Inc., Compumedics Limited, CSL Limited, Drive, Devilbiss Healthcare.
North America contribute notably towards the global Sleeping Aids Market.
The global sleeping aids market expected to grow at a CAGR of 6.8% during the forecast period.
The Sleeping Aids Market report covering key are product, sleep disorders, and region.
© 2024 Polaris Market Research and Consulting. All rights reserved
